Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Aims: To assess the efficacy and safety of adjunctive saxagliptin vs glimepiride in elderly patients with type 2 diabetes ( T2D ) and inadequate glycaemic control. Methods: In this multinational, randomized, double‐blind, phase IIIb / IV study ( GENERATION ; NCT01006603 ), patients aged ≥65 years were randomized (1 : 1) to receive saxagliptin 5 mg/day or glimepiride ≤6 mg/day, added to metformin, during a 52‐week treatment period. The primary endpoint was achievement of glycated haemoglobin ( HbA1c ) <7.0% at week 52 without confirmed/severe hypoglycaemia. The key secondary endpoint was incidence of confirmed/severe hypoglycaemia. Safety and tolerability were also assessed. Results: Of 720 patients randomized (360 in each treatment group; mean age 72.6 years; mean T2D duration 7.6 years), 574 (79.8%) completed the study (saxagliptin 80.3%; glimepiride 79.2%). Similar proportions of patients achieved the primary endpoint with saxagliptin and glimepiride (37.9 vs 38.2%; odds ratio 0.99, 95% confidence interval 0.73, 1.34; p = 0.9415); however, a significant treatment‐by‐age interaction effect was detected (p = 0.0389): saxagliptin was numerically (but not significantly) superior to glimepiride for patients aged <75 years (39.2 vs 33.3%) and numerically inferior for patients aged ≥75 years (35.9 vs 45.5%). The incidence of confirmed/severe hypoglycaemia was lower with saxagliptin vs glimepiride (1.1 vs 15.3%; nominal p < 0.0001). Saxagliptin was generally well tolerated, with similar incidences of adverse events compared with glimepiride. Conclusion: As avoiding hypoglycaemia is a key clinical objective in elderly patients, saxagliptin is a suitable alternative to glimepiride in patients with T2D aged ≥65 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“The overall cardiovascular safety with saxagliptin was previously assessed in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) study of ∼16 500 patients with T2D with a history of, or at risk of, cardiovascular events [30].”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 4×
“0% may no longer be considered appropriate for certain elderly patients [5,21].”
BackgroundMethodInfluentialDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“In elderly patients with diabetes, the risk of hypoglycaemia is substantially higher compared with younger adults [1,2] and the harm associated with severe hypoglycaemia may counterbalance the potential benefits of intensive glucose control [3,4].”
BackgroundDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803 · cited 1×
“In elderly patients with diabetes, the risk of hypoglycaemia is substantially higher compared with younger adults [1,2] and the harm associated with severe hypoglycaemia may counterbalance the potential benefits of intensive glucose control [3,4].”
BackgroundGoto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492 · cited 1×
“Severe hypoglycaemia has been shown to be associated with an increased risk of cardiovascular disease and severe ventricular arrhythmias [19,20].”
BackgroundSinclair, A., Morley, J. E., Rodriguez-Mañas, L., Paolisso, G., Bayer, T., Zeyfang, A., Bourdel-Marchasson, I., Vischer, U., Woo, J., Chapman, I., et al. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.04.012 · Cited by 422 · cited 2×
“0% may no longer be considered appropriate for certain elderly patients [5,21].”
BackgroundSelf-citationDeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416 · cited 1×
“In Phase III studies, saxagliptin improved glycaemic control vs placebo and was similar to active comparators (glipizide or sitagliptin), in combination with metformin [7-9], metformin plus glimepiride [10], other oral antihyperglycaemic drugs [11,12] or insulin [13].”
Backgroundfor the ADVANCE Collaborative Group, Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M. E., Colagiuri, S., Fulcher, G., de Galan, B. E., Harrap, S., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2404-1 · Cited by 358 · cited 1×
“0%, respectively [17], intensive glycaemic control may have either no influence or potentially a detrimental effect on cardiovascular outcomes in patients with a relatively long duration of diabetes and risk factors for cardiovascular disease [18].”
BackgroundHypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes
Bremer, J. P., Jauch-Chara, K., Hallschmid, M., Schmid, S., & Schultes, B. (2009) · Diabetes Care · doi:10.2337/dc09-0114 · Cited by 298
Schernthaner, G., Grimaldi, A., Di Mario, U., Drzewoski, J., Kempler, P., Kvapil, M., Novials, A., Rottiers, R., Rutten, G. E. H. M., & Shaw, K. M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01381.x · Cited by 271 · cited 1×
“Furthermore, hypoglycaemia incidence with glimepiride is higher in patients with mild renal impairment than in those with normal renal function [24]; however, in the present study, the increased glimepiride efficacy in patients aged≥75 years”
ResultSelf-citationSymptoms of hypoglycaemia in people with diabetes
McAulay, V., Deary, I. J., & Frier, B. M. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00620.x · Cited by 264
Stahn, A., Pistrosch, F., Ganz, X., Teige, M., Koehler, C., Bornstein, S., & Hanefeld, M. (2014) · Diabetes Care · doi:10.2337/dc13-0600 · Cited by 173
Self-citation
Cited by
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 286
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
“We identified one new study that would fulfill the inclusion criteria of this review [88].”
BackgroundKalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
Overbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71
“The full texts of the remaining studies were evaluated for the inclusion and exclusion criteria, which resulted in a final inclusion of 25 studies.(2,3,17-39) For 4 studies, the authors were contacted, because the publications did not contain sufficient information regarding risk or variables needed to calculate the r…”
Background
Metadata
- Authors
- Schernthaner, G., Durán‐Garcia, S., Hanefeld, M., Langslet, G., Niskanen, L., Östgren, C. J., Malvolti, E., & Hardy, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-04-07
- Volume
- 17
- Issue
- 7
- Pages
- 630-638
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1982202068
- Cited by
- 64
- References
- 16
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.